Aminacrine

Aminacrine

SCHEMBL7124412

Nc1c2ccccc2nc2ccccc12.O=C(NO)ON1C(=O)CCC1=O

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 7/20 0.46
HSD17B10 Q99714 6/20 0.46
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 5/20 0.46
GLA P06280 3/20 0.46
HPGD P15428 3/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CHRM2 P08172 2/20 0.46
ADRA2A P08913 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
CHRM1 P11229 2/20 0.46
SLC6A2 P23975 2/20 0.46
OPRM1 P35372 2/20 0.46
KCNH2 Q12809 2/20 0.46
NQO2 P16083 1/20 0.46
MAOA P21397 1/20 0.46
DRD1 P21728 1/20 0.46
ADRA1A P35348 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116680 0.83 NCF1 (0.53) LMNAPOLBMAPTHTTKMT2A
SCHEMBL9296399 0.80 HTR3A (0.43) ACHEHSD17B10KDM4EALDH1A1GLA
SCHEMBL3143334 0.75 KDM4E (0.44) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL4163816 0.75 PSMB8 (0.39) ACHEHSD17B10KDM4EALDH1A1GLA
SCHEMBL3259839 0.72 ALDH1A1 (0.52) HSD17B10KDM4EALDH1A1CASP1SMN1; SMN2
Ethylenediamine SCHEMBL9297163 0.71 ALOX12 (0.30) PARL
Acridine SCHEMBL7872845 0.70 ALDH1A1 (0.46) ACHEKDM4EALDH1A1GLAHPGD
SCHEMBL16261005 0.68 NPC1 (0.50) SMN1; SMN2ADORA3RAB9AMAPTKMT2A
SCHEMBL1205198 0.68 SMN1; SMN2 (0.51) ACHEKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL9296664 0.68 PARP1 (0.35) HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6632629-B2 Microfluidic in-line labeling method of continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2003-10-14 US claimed
US-20030064425-A1 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2003-04-03 US claimed
US-6468761-B2 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES, CORP. 2002-10-22 US claimed
US-20010026929-A1 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2001-10-04 US claimed
EP-0533200-A1 Preparation and use of novel activated carbamates WATERS INVESTMENTS LIMITED (US) 1993-03-24 EP claimed
US-6632629-B2 Microfluidic in-line labeling method of continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2003-10-14 US disclosed
US-20030064425-A1 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2003-04-03 US disclosed
US-6468761-B2 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES, CORP. 2002-10-22 US disclosed
US-20010026929-A1 Microfluidic in-line labeling method for continuous-flow protease inhibition analysis CALIPER TECHNOLOGIES CORP. 2001-10-04 US disclosed
US-5296599-A Activated carbamates compounds MILLIPORE CORPORATION (US) 1994-03-22 US disclosed
EP-0533200-A1 Preparation and use of novel activated carbamates WATERS INVESTMENTS LIMITED (US) 1993-03-24 EP disclosed